NRx Pharmaceuticals announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals, will present a corporate overview at the BIO CEO & Investor Conference, which is scheduled to take place February 26-27, 2024, at the Marriott Marquis in New York City. “Subsequent to our announcement last week, we are in the process of completing a Memorandum of Understanding that may enable us to begin sales of IV ketamine to qualified clinics in partnership with a holder of a nationwide pharmacy license. Additionally, we will be updating investors with regard to our plans to add a digital therapeutic component to our ketamine offering that has potential to extend the clinical benefit to patients.” said Dr. Javitt. “We thank our investors for their support and look forward to updating the public on our progress towards building a lifesaving therapy.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NRXP:
- NRX Pharmaceuticals Amends Repayment Terms with Streeterville Capital
- NRx Pharmaceuticals Secures Funding and Expands Alvogen Partnership
- NRx Pharmaceuticals receives $5M milestone payment
- NRx reports comments from its partner Lotus on its recent financial filing
- NRx Pharmaceuticals announces incorporation of Hope Therapeutics